The great obesity drug scare of 2023 is now behind ResMed as evidence in the December quarter suggests GLP-1s are actually a positive for the sleep apnoea industry ...

Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines ... of digital solutions in homecare settings. ResMed’s adjusted gross margin improved ...